1 terminated, 1 withdrawn. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Carman Giacomantonio: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma Interleukin-2, Combination therapy Interleukin-2 and Bacillus Calmette Guerin - Cutaneous Metastatic Melanoma | Phase 2 / Phase 3 | Withdrawn | Carman Giacomantonio | 2021-12-01 | 2023-02-14 | |
| Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2 Aldesleukin, Saline - Melanoma (Skin), Melanoma in Situ | Phase 3 | Terminated | Carman Giacomantonio | 1 | 2019-10-30 | 2024-07-24 |
Melanoma (1)
aldesleukin (2) · BCG Vaccine (1) · Interleukin-2 (1) · Sodium Chloride (1)
Canada (1)
Carman A Giacomantonio, MD (1) · Carman A Giacomantonio, MD, FRCSC (1)